Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With <i>FGFR</i> RNA-Overexpressing Urothelial Cancer
- DOI
- 10.1001/jamaoncol.2024.3900
- Published
- 2024-11-01
- Container
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1001/jamaoncol.2024.3900,
title = {Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With <i>FGFR</i> RNA-Overexpressing Urothelial Cancer},
author = {Randy F. Sweis and Pablo Gajate and Rafael Morales-Barrera and Jae-Lyun Lee and Andrea Necchi and Filippo de Braud and Nicolas Penel and Viktor Grünwald and Marco Maruzzo and Johannes Meran and Tatiane Cristine Ishida and Weichao Bao and Yinghui Zhou and Peter Ellinghaus and Jonathan E. Rosenberg},
year = {2024},
journal = {JAMA Oncology},
doi = {10.1001/jamaoncol.2024.3900},
url = {https://doi.org/10.1001/jamaoncol.2024.3900}
}RIS
TY - JOUR TI - Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With <i>FGFR</i> RNA-Overexpressing Urothelial Cancer AU - Randy F. Sweis AU - Pablo Gajate AU - Rafael Morales-Barrera AU - Jae-Lyun Lee AU - Andrea Necchi AU - Filippo de Braud AU - Nicolas Penel AU - Viktor Grünwald AU - Marco Maruzzo AU - Johannes Meran AU - Tatiane Cristine Ishida AU - Weichao Bao AU - Yinghui Zhou AU - Peter Ellinghaus AU - Jonathan E. Rosenberg PY - 2024 JO - JAMA Oncology DO - 10.1001/jamaoncol.2024.3900 UR - https://doi.org/10.1001/jamaoncol.2024.3900 ER -
APA
Sweis, R. F., Gajate, P., Morales-Barrera, R., Lee, J., Necchi, A., Braud, F. D., Penel, N., Grünwald, V., Maruzzo, M., Meran, J., Ishida, T. C., Bao, W., Zhou, Y., Ellinghaus, P., & Rosenberg, J. E. (2024). Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With <i>FGFR</i> RNA-Overexpressing Urothelial Cancer. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2024.3900
Source records
- crossref · retrieved 2026-09-26T06:08:19.740Z